Business
Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced a further expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for India.
About this update from Bio-thera Solutions, Ltd. Class A
[{"type":"text","content":"GUANGZHOU, China, March 23, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced a further expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for India.","length":394,"tagName":"p"},{"type":"image","alt":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America (PRNewsfoto/Bio-Thera Solutions, Ltd)","displaySize":"","headline":null,"caption":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America (PRNewsfoto/Bio-Thera Solutions, Ltd)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":164,"url":"https://media.zenfs.com/en/prnewswire.com/9ba3417a034ec44b6148845f431884f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qTgeC.CM1hCASG.1efQpLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4OQ--/https://media.zenfs.com/en/prnewswire.com/9ba3417a034ec44b6148845f431884f4","width":400,"height":164}},"href":"https://mma.prnewswire.com/media/2616491/Bio_Thera_and_Intas.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-), a pro-inflammatory molecule. Binding of golimumab to TNF- results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. The reference medicine golimumab has been approved in the Canada for several indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.","length":638,"tagName":"p"},{"type":"text","content":""We are pleased to further expand our partnership with Intas for BAT2506 by now adding Indian commercialization rights to the partnership", said...